若不治疗耐多药结核病的危险。
The risk of leaving multidrug-resistant tuberculosis untreated.
应对耐多药结核病方面取得的进展
但这些病例中有多少是耐多药结核病？
预防和控制耐多药结核病和广泛耐药结核病。
Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.
问：你什么时候开始介入耐多药结核病问题的？
因此，出现各种耐多药结核病管理不善的情况。
As a result all kinds of poor management of MDR-TB are happening.
什么是耐多药结核和广泛耐药结核的医学定义？
这就是耐多药结核病的出现和传播所带来的前景。
This is the perspective created by the emergence and spread of drug-resistant tuberculosis.
在2006年，估计有50万例耐多药结核病例。
There were an estimated 0.5 million cases of multidrug-resistant TB (MDR-TB) in 2006.
2007年，耐多药结核病例估计数为50万例。
There were an estimated 0.5 million cases of multidrug-resistant TB (MDR-TB) in 2007.
在这段时间内，患者有可能把耐多药疾病传给他人。
During this period, they can spread the multidrug-resistant disease to others.
问：你对与耐多药结核病作斗争的前途有什么看法？
开发抗击耐多药/广泛耐药结核病所需要的新工具。
对普通结核病的不规范治疗致使耐多药菌株滋生繁殖。
Substandard treatment of normal TB drives the development of multi-drug resistant strains.
这不仅意味着拯救耐多药结核病人，也拯救所有的人。
That means not only saving the people with MDR-TB but also the general population.
在研究的544名患者中，有221人患有耐多药结核。
问：哈萨克斯坦与耐多药结核病作斗争的核心内容是什么？
Q: What's the most important part of Kazakhstan's fight against drug-resistant TB?
这相当于痰涂阳性的耐多药结核病例全球估计总数的1%。
This is equivalent to 1% of the estimated global total of smear-positive cases of MDR-TB.
在美国，4%的耐多药结核病例符合广泛耐药结核的标准。
In the United States, 4% of MDR-TB cases met the criteria for XDR-TB.
估计全世界将近50%的耐多药结核病例发生在中国和印度。
Almost 50% of MDR-TB cases worldwide are estimated to occur in China and India.
耐多药结核病是一种对一线标准药物没有反应的结核病形式。
MDR-TB is a form of TB that fails to respond to standard first-line drugs.
这仅相当于痰涂阳性耐多药结核病例全球估计总数的8.5%。
This was 8.5% of the estimated global total of smear-positive cases of MDR-TB.
菲律宾像世界任何国家一样，长期以来设法控制耐多药结核病。
The Philippines has tried to control multidrug-resistant TB (MDR -TB ) for nearly as long as any country in the world.
问：除了钱外，什么是开展耐多药结核病治疗规划的最重要因素？
Q: Aside from money, what has been the most important factor in running a MDR-TB treatment programme?
结核病控制在稳步取得进步，但耐多药结核病却达到了历史较高水平。
Progress in tuberculosis control remains steady but multi-drug resistant TB has reached historic levels.
形成耐多药结核或广泛耐药结核的第二个途径是患者自身的结核产生耐药性。
A second way of developing MDR-TB or XDR-TB is when a patient's own TB develops resistance.
用二线药物治疗耐多药结核所需时间更长，更加昂贵，并且产生更多副作用。
MDR-TB takes longer to treat with second-line drugs, which are more expensive and have more side-effects.
耐多药结核病的蔓延引起了人们的特别关注，尤其是在东欧、中亚部分和中国。
The spread of multi-drug resistant TB is a cause of particular concern, especially in Eastern Europe, parts of Central Asia, and China.
耐多药结核病的蔓延引起了人们的特别关注，尤其是在东欧、中亚部分和中国。
The spread of multi-drug resistant TB is a cause of particular concern, especially in Eastern Europe, parts of Central Asia, and China.
应用推荐